Kuchyne na miru

R&D

Aug 12, 2019
Pharmaceutical Executive
Pharm Exec speaks with Geoff MacKay, CEO of AVROBIO, about the company’s mission to advance potentially curative lentiviral-based gene therapies and moving gene therapy into the mainstream.
Jul 10, 2019
Cell One Partners' George Goldberger discusses the issues that new and emerging cell and gene therapy companies face on the road to commercialization.
Jul 06, 2019
By Pharmaceutical Executive Editors
Jan Lichtenberg, Ph.D, and Scott Friedman, MD, talk about the growing interest in nonalcoholic steatohepatitis (NASH) in the pharma industry, the complexities of modeling the disease, and what this means for drug development efforts.
Jun 11, 2019
Pharmaceutical Executive
By David Roblin
With little momentum in developing new antibiotics to fight antimicrobial resistance, writes Dave Roblin, the time is now to emphasize "push" and "pull" incentives and demonstrate how innovation in this area will lead to patient benefit and economic reward.
May 17, 2019
Jianan Huang discusses how the drug revenue formula is being used to guide R&D "rescue strategies".
May 02, 2019
Given the complexities of clinical trials, however, accurate updating of actual and forecasted site payments for real-time reporting remains one of the largest challenges in medical product development, writes Shaun Williams.
Nov 13, 2018
Emil Eifrem examines how researchers at Munich’s German Center for Diabetes Research are uncovering insights with a new way of working with complex data.
Nov 13, 2018
Pharmaceutical Executive
Amid a still-difficult environment for enforcing cannabis-related patents, Eric Furman and Ari Feinstein explore the types of patent protection available for cannabis-based therapies and inventions.
Nov 06, 2018
Pharmaceutical Executive
By Meghan Oates-Zalesky
Data shows cultural gaps and highlights a C-level fix, writes Meghan Oates-Zalesky.
native1_300x100
fashioncarpet.com.ua

cafemarseille.com.ua

adulttorrent.org/search/Hookers
lorem ipsum